AMGEN presents ‘encouraging’ AMG 133 weight loss results
Amgen revealed new Phase 1 data from AMG 133, a novel bispecific glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist...
top of page
Browse by category
Search
ICER finds semaglutide more effective, but more expensive
The Institute for Clinical and Economic Review (ICER) in the US has published its revised Evidence Report assessing the comparative...
Innovent starts Phase 2 Clinical Trial of mazdutide in Chinese adults with obesity
Innovent Biologics has announced that the first participant has been successfully dosed in the higher-dose cohort of a phase 2 clinical...
Browse by tag
bottom of page